Related Experiment Video
Updated: Apr 18, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Incidence and risk of xerosis with targeted anticancer therapies
Johannah Valentine1, Viswanath Reddy Belum2, Juanita Duran3
1Department of Dermatology, Naval Medical Center San Diego, San Diego, California.
Background:
Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained.
Objective:
We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs.
Methods:
The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models.
Results:
The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P < .001).
Limitations:
The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions.
Conclusion:
Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment.
Insights
Targeted cancer therapies significantly increase the risk of xerosis (dry skin). This systematic review found a 17.9% incidence, highlighting the need for early patient counseling and treatment to maintain quality of life.
Area of Science:
- Oncology
- Dermatology
- Clinical Pharmacology
Background:
- Targeted cancer therapies are associated with xerosis (dry skin).
- The precise incidence and relative risk of xerosis from these treatments remain unclear.
Purpose of the Study:
- To systematically review and meta-analyze clinical trials.
- To determine the incidence and risk of xerosis in patients receiving anticancer drugs.
Main Methods:
- Searched PubMed, Web of Science, and ASCO abstracts (1966-2013).
- Included clinical trials involving 58 targeted anticancer agents.
- Utilized random or fixed effects models for results calculation.
Main Results:
- Overall incidence of xerosis was 17.9% (95% CI: 15.6-20.4%).
- High-grade xerosis incidence was 1.0% (95% CI: 0.9-1.5%).
- The risk of developing any-grade xerosis was 2.99 (95% CI: 2.0-4.3), varying by drug.
Conclusions:
- Patients on targeted therapies face a significant risk of xerosis.
- Xerosis reporting may be inconsistent.
- Early patient counseling and treatment are crucial for managing xerosis, preventing dose reduction, and preserving quality of life.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Acne Infection